Original Article
  

A Randomized Control Trial Study to Determine the Effect of Melatonin on Serum Levels of IL-1β and TNF-α in Patients with Multiple Sclerosis

Abstract

Multiple sclerosis (MS) is the most common neurological disease that happens at a young age. MS is an inflammatory disease; associated with the demyelination of the central nervous system. Therefore, some inflammatory factors are effective in the mechanism and progression of the disease. Melatonin, as a multi-effect substance including anti-inflammatory effects, can reduce symptoms of MS in patients with a change in their inflammatory factors level. In this study, 50 MS patients who were referred to the MS Society of Markazi Province were randomly selected. All patients were treated with routine MS treatment (interferon) and were divided into control (25 placebo recipients) and treatment (25 recipients of 3 mg melatonin per day for 24 weeks) groups. Anthropometric data of patients including height, weight, and age were determined. Blood samples were collected after fasting in order to determine serum levels of interleukin 1 beta (IL-1β) and tumor necrosis factor-alpha (TNF-α). Then, samples were immediately centrifuged for serum separation and sera were transferred to a freezer at -80°C and serum levels of these factors were determined; using ELISA kit. The results of this study showed that there was no significant difference between the control and treatment groups in terms of serum levels of TNF-α. However, the level of IL-1β was significantly reduced in the treatment group compared to the control group, indicating that melatonin decreases this inflammatory substance. Our findings suggest a valuable strategy in the treatment of patients who suffer from MS.

1. Stein EM, Gennuso KP, Ugboaja DC, Remington PL. The epidemic of despair among White Americans: trends in the leading causes of premature death, 1999–2015. Am J public health 2017; 107(10):1541-7.
2. Oksenberg JR, Barcellos LF. The complex genetic aetiology of multiple sclerosis. Journal of Neurovirology 2000; 6(2):10.
3. Ontaneda DH, Cohen MJ. A Multiple sclerosis: new insights in pathogenesis and novel therapeutics. Annu Rev Med 2012; 63:389-404.
4. Mahad DH, Trapp BD, Lassmann H. Pathological mechanisms in progressive multiple sclerosis. Lancet Neurol 2015; 14(2):183-93.
5. Pröbstel AK, Sanderson NSR, Derfuss T. B cells and autoantibodies in multiple sclerosis. Int J Mol Sci 2015; 16(7):16576-92.
6. Martins GR,Gelaleti GB,Moschetta MG,Maschio-Signorini LB,Zuccari DA. Proinflammatory and anti-inflammatory cytokines mediated by NF-κB factor as prognostic markers in mammary tumors. Mediators Inflamm J 2016; 2016:9512743.
7. Caminero A, Comabella M, Montalban X. Tumor necrosis factor alpha (TNF-α), anti-TNF-α and demyelination revisited: an ongoing story. J Neuroimmunol 2011; 234(1-2):1-6.
8. Martin JP, Janette B, Etheresia p. The inflammatory effects of TNF-α and complement component 3 on coagulation. Sci Rep 2018; 8(1):1812.
9. Lim S, Cris SC. TNF-α: A paradigm of paradox and complexity in multiple sclerosis and its animal models. OpenAutoimmunJ 2010; 2(1):160-70.
10. Akash MSH, Rehman K, Liaqat A. Tumor Necrosis Factor-Alpha: Role in Development of Insulin Resistance and Pathogenesis of Type 2 Diabetes Mellitus. J Cell Biochem 2018; 119(1):105-10.
11. Gao W, Kumar S, Lotze MT, Hanning C, Robbins PD, Gambotto A. immunity mediated by the cytokine IL-1 homologue 4 (IL-1H4/IL-1F7) induces IL-12-dependent adaptive and profound antitumor immunity. J Immunol 2003; 170(1):107-13.
12. Dinarello CA. Overview of the IL-1 family in innate inflammation and acquired immunity. Immunol Rev2018; 281(1):8-27.
13. Paré A,Mailhot B, Lévesque SA, Lacroix S. Involvement of the IL-1 system in experimental autoimmune encephalomyelitis and multiple sclerosis: Breaking the vicious cycle between IL-1β and GM-CSF. Brain Behav Immun2017; 62:1-8.
14. Mendiola AS, Cardona AE. The IL-1β phenomena in neuroinflammatory diseases. J Neural Transm (Vienna) 2018; 125(5):781-95.
15. Hardeland R, Cardinali DP, Srinivasan V,Spence DW,Brown GM,Pandi-Perumal SR. Melatonin—a pleiotropic, orchestrating regulator molecule. Prog Neurobio 2011; 93(3):350-84.
16. Liu J, Clough SJ, Hutchinson AJ, Adamah-Biassi EB,Popovska-Gorevski M,Dubocovich ML. MT1 and MT2 melatonin receptors: a therapeutic perspective. Annu Rev Pharmacol Toxicol 2016; 56:361-83.
17. Russel JR, Lucien C M, Dun XT. free radical mechanisms and melatonin protection. Curr Neuropharmacol 2010; 8(3):194–210.
18. Sun H and et al. Melatonin Treatment Improves Insulin Resistance and Pigmentation in Obese Patients with Acanthosis Nigricans. J Endocrinol 2018; 2018:46-7.
19. Esposito E, Cuzzocrea S. Antiinflammatory activity of melatonin in central nervous system. Curr Neuropharmacol 2010; 8(3):228–42.
20. Nabavi SM and et al. Anti-inflammatory effects of Melatonin: A mechanistic review. Crit Rev Food Sci Nutr 2018; 14:1-13.
21. Akpinar Z, Tokgöz S, Gökbel H, Okudan N, Uğuz F,Yilmaz G. The association of nocturnal serum melatonin levels with major depression in patients with acute multiple sclerosis. Psychiatry Res 2008; 30:161(2):253-7.
22. Tan DX, Xu B, Zhou X, Reiter RJ. Pineal calcification, melatonin production, aging, associated health consequences and rejuvenation of the pineal gland. Molecules 2018; 23(2):301.
23. Sugden D, Davidson K, Hough KA, Teh MT. Melatonin, melatonin receptors and melanophores: a moving story. Pigment Cell Res 2004; 17(5):454-60.
24. Wen J and et al. Efficacy of N-acetylserotonin and melatonin in the EAE model of multiple sclerosis. J Neuroimmune Pharmacol2016; 11(4):763-73.
25. Mason JL, Suzuki K, Chaplin DD, Matsushima GK. Interleukin-1β promotes repair of the CNS. J Neurosci 2001; 21(18):7046-52.
26. Chih ChL, Brain TE. New Insights into the Role of IL-1β in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis. J Immunol 2017; 198(12):4553-60.
27. Liu Zh and et al. Melatonin alleviates inflammasome induced pyroptosis through inhibiting NF‐κB/GSDMD signal in mice adipose tissue. J Pineal Res2017; 63(1):12414.
28. Sharief MK, Hentges R. Association between tumor necrosis factor-α and disease progression in patients with multiple sclerosis. N Engl J Med1991; 325(7):467-72.
29. Göbel K, Ruck T, Meuth SG. Cytokine signaling in multiple sclerosis: Lost in translation. Mult Scler 2018; 24(4):432-39.
30. Farhadi N,Oryan S, Nabiuni M. Serum levels of melatonin and cytokines in multiple sclerosis. Biomed J 2014; 37(2):90-2.
31. Alimoradian A, Shamsi M, Faraji F, Ahmadi M, Sayyed Sayyedi E, Evaluation of the Serum Melatonin Levels in the Treatment of Patients with Multiple Sclerosis. J Evaluation 2018; 21(131):55-64.
32. Jamshidi fard A, RH Faraji F, Ahmadi M, Sayeddi SE. Effects of melatonin on visual functioning of patients with multiple sclerosis.J Arak Uni Med Sci 2018; 21(2):55-64.
33. Wurtman R. Multiple Sclerosis, Melatonin, and Neurobehavioral Diseases. Front Endocrinol 2017; 8:280.
Files
IssueVol 18, No 6 (2019) QRcode
SectionOriginal Article(s)
DOI https://doi.org/10.18502/ijaai.v18i6.2177
PMID32245308
Keywords
Interleukin 1 beta Multiple sclerosis Melatonin Tumor necrosis factor-alpha
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Yosefifard M, Vaezi G, Malekirad AA, Faraji F, Hojati V. A Randomized Control Trial Study to Determine the Effect of Melatonin on Serum Levels of IL-1β and TNF-α in Patients with Multiple Sclerosis. Iran J Allergy Asthma Immunol. 2019;18(6):649-654.